Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGDS | O60760 | 2/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | STS | P08842 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 3/20 | 0.48 |
| ▸ | MAPT | P10636 | 3/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.48 |
| ▸ | CNR1 | P21554 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10070506 | 0.88 | HPGDS (0.53) | HPGDSSMN1; SMN2TP53MAPTHTT | |
| SCHEMBL1653375 | 0.88 | CNR1 (0.53) | HPGDSSMN1; SMN2STSTP53MAPT | |
| SCHEMBL1653217 | 0.88 | HPGDS (0.64) | HPGDSSMN1; SMN2HTTHSD11B1MEN1 | |
| SCHEMBL310851 | 0.83 | SMN1; SMN2 (0.49) | HPGDSSMN1; SMN2STSTP53MAPT | |
| SCHEMBL10070063 | 0.82 | HTT (0.48) | HPGDSSMN1; SMN2MAPTPOLBCNR1 | |
| SCHEMBL10069708 | 0.82 | HPGDS (0.52) | HPGDSSMN1; SMN2MAPTPOLBHTT | |
| SCHEMBL10069537 | 0.81 | HSD11B1 (0.43) | SMN1; SMN2HSD11B1 | |
| SCHEMBL10069714 | 0.81 | HSD11B1 (0.43) | HSD11B1MEN1KMT2A | |
| SCHEMBL17801068 | 0.79 | HTT (0.47) | HPGDSMAPTCNR1HTTMEN1 | |
| SCHEMBL10070098 | 0.78 | CPT2 (0.51) | HPGDSSMN1; SMN2TP53MAPTHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8207199-B2 | Azole compound | ASTELLAS PHARMA INC. (JP) | 2012-06-26 | — | — | US | disclosed |
| US-20110118311-A1 | AZOLE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2011-05-19 | — | — | US | disclosed |
| WO-2010007966-A1 | AZOLE COMPOUND | アステラス製薬株式会社 (JP) | 2010-01-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110118311-A1 | AZOLE COMPOUND | FAAH, FAAH2, TRPV1 | HPGDS 1623/4885SMN1; SMN2 1891/4885STS 2332/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.